Cerebellum-based Imaging Neural Markers for Antipsychotic Response

This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.

NCT Number	NCT07483294
Lead Sponsor	Northwell Health Collaborators: National Institute of Mental Health (NIMH)
Conditions	Psychosis; Acute
Enrollment	120 participants
Start Date	2025-11-01
Primary Completion	2029-12-01 (estimated)
Study Completion	2030-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-26